#	Pagina
attuale pagina	/open-h2020/projects/206747/index.html

Opendata, web and dolomites

CUPIDO SIGNED

Cardio Ultraefficient nanoParticles for Inhalation of Drug prOducts

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

CUPIDO project word cloud

Explore the words cloud of the CUPIDO project. It provides you a very rough idea of what is the project "CUPIDO" about.

clinically worldwide incidence cardiovascular euros significantly cd diseases start limitations clinical pharmacological innovative unconventional malignant urgent nanoparticles biodegradable meet nanomedical combination drug biologicals crossing globally offers diseased individuals translation billion medical efforts 139 highlights 17 40 day regulatory barriers difficulties final manufacturing breaking respect formulated mortality disease heart hybrid bioinspired altogether elderly therapeutic safe lives treatments multidisciplinary biological envisioned regimens therapeutics deaths ground million validation employed strategy overcome instability biocompatible designed therapies strategies nanoparticle critical 31 claims cardiac guidable efficient unspecific assisted cupido toward

Project "CUPIDO" data sheet

The following table provides information about the project.

Coordinator	CONSIGLIO NAZIONALE DELLE RICERCHE Organization address address: PIAZZALE ALDO MORO 7 city: ROMA postcode: 185 website: www.cnr.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Italy [IT]
Project website	http://www.cupidoproject.eu
Total cost	6˙094˙781 €
EC max contribution	6˙094˙781 € (100%)
Programme	1. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
Code Call	H2020-NMBP-2016-two-stage
Funding Scheme	RIA
Starting year	2017
Duration (year-month-day)	from 2017-02-01 to 2021-01-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	CONSIGLIO NAZIONALE DELLE RICERCHE CONSIGLIO NAZIONALE DELLE RICERCHE Organization address address: PIAZZALE ALDO MORO 7 city: ROMA postcode: 185 website: www.cnr.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (ROMA)	coordinator	1˙800˙141.00
2	IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE Organization address address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD city: LONDON postcode: SW7 2AZ website: http://www.imperial.ac.uk/ contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (LONDON)	participant	689˙983.00
3	FIN-CERAMICA FAENZA SPA FIN-CERAMICA FAENZA SPA Organization address address: Via Granarolo 177/3 city: FAENZA postcode: 48018 website: www.finceramica.it contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (FAENZA)	participant	490˙000.00
4	CHARITE - UNIVERSITAETSMEDIZIN BERLIN CHARITE - UNIVERSITAETSMEDIZIN BERLIN Organization address address: Chariteplatz 1 city: BERLIN postcode: 10117 website: www.charite.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (BERLIN)	participant	484˙585.00
5	SIMULA RESEARCH LABORATORY AS SIMULA RESEARCH LABORATORY AS Organization address address: MARTIN LINGES VEI 17 city: FORNEBU postcode: 1364 website: www.simula.no contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NO (FORNEBU)	participant	442˙338.00
6	NEMERA LA VERPILLIERE NEMERA LA VERPILLIERE Organization address address: 20 AVENUE DE LA GARE city: LA VERPILLIERE postcode: 38292 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (LA VERPILLIERE)	participant	400˙000.00
7	BIOEMISSION TECHNOLOGY SOLUTIONS IKE BIOEMISSION TECHNOLOGY SOLUTIONS IKE Organization address address: ALEXANDRAS AVENUE 116 city: ATHINA postcode: 114 72 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	EL (ATHINA)	participant	351˙750.00
8	CAMBRIDGE INNOVATION TECHNOLOGIES CONSULTING LIMITED CAMBRIDGE INNOVATION TECHNOLOGIES CONSULTING LIMITED Organization address address: ST JOHN'S INNOVATION CENTRE COWLEY ROAD city: CAMBRIDGE postcode: CB4 0WS website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	UK (CAMBRIDGE)	participant	314˙913.00
9	L.I.F.E. ITALIA SRL L.I.F.E. ITALIA SRL Organization address address: VIA PRIVATA DELLA TORRE 11 city: MILANO postcode: 20127 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (MILANO)	participant	300˙875.00
10	IN SRL IN SRL Organization address address: VIA CARDUCCI 9A city: UDINE postcode: 33100 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (UDINE)	participant	300˙285.00
11	PLUMESTARS SRL PLUMESTARS SRL Organization address address: STRADA INZANI 1 city: PARMA PR postcode: 43124 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	IT (PARMA PR)	participant	300˙000.00
12	SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT Organization address address: Pierre Brossolette 1 city: Chilly Mazarin postcode: 91380 website: www.sanofi-aventis.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (Chilly Mazarin)	participant	219˙908.00
13	LIFE CORPORATION SA LIFE CORPORATION SA Organization address address: 20 RUE JEAN-PIERRE BEICHT city: LUXEMBOURG postcode: 1226 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	LU (LUXEMBOURG)	participant	0.00

Map

Project objective

The incidence of Cardiovascular Disease (CD) claims worldwide 17.1 million lives a year, with an estimated 31% of all deaths globally and a EU cost of 139 billion euros. Up to 40% of all deaths occur among the elderly. In spite of all medical efforts, the 5-year mortality was reduced significantly less than that of malignant diseases. This highlights the urgent need to overcome the difficulties associated with present pharmacological therapies (i.e. drug instability, and unspecific targeting) by developing new ground-breaking therapeutic strategies that go far beyond any current regimens. New approaches for safe, efficient, and heart-specific delivery of therapeutics are strongly required. CUPIDO is envisioned to meet these critical needs by providing an unconventional and effective strategy based on nanoparticle-assisted delivery of clinically available and novel therapeutics to the diseased heart. In particular, CUPIDO will develop innovative bioinspired hybrid nanoparticles formulated as biologicals delivery, which are i) biocompatible and biodegradable, ii) designed for crossing biological barriers, and iii) guidable to the heart. A combination of multidisciplinary manufacturing and validation approaches will be employed, bringing the envisioned product beyond the currently available clinical and day-to-day management of CD individuals. Scale-up production, and respect of medical regulatory requirements will allow CUPIDO to deliver a final product for future late pre-clinical and clinical studies. Altogether, CUPIDO will foster the translation of nanomedical applications toward the cardiac field, which although still in its start, offers great potential to overcome the limitations associated to the currently pharmacological treatments.

Deliverables

List of deliverables.
Extended model, describing relationship between FeCaPs and deposition site when exposed to an external magnetic field (M12)	Documents, reports	2020-04-08 11:30:38
Distribution of electromagnetic fields in the target area due to the drug targeting systems	Documents, reports	2020-04-08 11:30:37
Visual identity kit (M12)	Documents, reports	2020-04-08 11:30:38
In vivo assessment of the studied nanopartilces using different imaging modalities (M12)	Documents, reports	2020-04-08 11:30:38
Summary of annual workshops and networking events building communities (M12)	Documents, reports	2020-04-08 11:30:38
Web portal, social media	Documents, reports	2020-04-08 11:30:38
Press releases (M3)	Documents, reports	2020-04-08 11:30:38
In vitro assessment of nanoparticle behavior at/across the pulmonary barrier (M12)	Documents, reports	2020-04-08 11:30:38
Extension of open-source flow simulation framework to also include porous media flow. Establish relationship between different nanoparticles and deposition sites in both small and large animal models (M18)	Documents, reports	2020-04-08 11:30:37
Summary of annual workshops and networking events building communities (M18)	Documents, reports	2020-04-08 11:30:38
Aptamer-mediated guidance of CaP (M12)	Documents, reports	2020-04-08 11:30:38
Press releases (M12)	Documents, reports	2020-04-08 11:30:38
Functional assessment (compatibility, physic-chemical and biological stability) of CaP restoration and drug release	Documents, reports	2020-04-08 11:30:37
E-newsletter (M12)	Documents, reports	2020-04-08 11:30:38
EMD-mediated guidance of FeCaP (M12)	Documents, reports	2020-04-08 11:30:38

Take a look to the deliverables list in detail: detailed list of CUPIDO deliverables.

Publications

List of publications.
year	authors and title	journal	last update
2018	Alessandra Marrella, Michele Iafisco, Alessio Adamiano, Stefano Rossi, Maurizio Aiello, Maria Barandalla-Sobrados, Pierluigi Carullo, Michele Miragoli, Anna Tampieri, Silvia Scaglione, Daniele Catalucci A combined low-frequency electromagnetic and fluidic stimulation for a controlled drug release from superparamagnetic calcium phosphate nanoparticles: potential application for cardiovascular diseases published pages: 20180236, ISSN: 1742-5689, DOI: 10.1098/rsif.2018.0236	Journal of The Royal Society Interface 15/144	2020-04-08
2018	Lorenzo Degli Esposti, Francesca Carella, Alessio Adamiano, Anna Tampieri, Michele Iafisco Calcium phosphate-based nanosystems for advanced targeted nanomedicine published pages: 1223-1238, ISSN: 0363-9045, DOI: 10.1080/03639045.2018.1451879	Drug Development and Industrial Pharmacy 44/8	2020-04-08
2018	Michele Miragoli, Paola Ceriotti, Michele Iafisco, Marco Vacchiano, NicolÃ² Salvarani, Alessio Alogna, Pierluigi Carullo, Gloria BelÃ©n Ramirez-RodrÃguez, Tatiana PatrÃcio, Lorenzo Degli Esposti, Francesca Rossi, Francesca Ravanetti, Silvana Pinelli, Rossella Alinovi, Marco Erreni, Stefano Rossi, Gianluigi Condorelli, Heiner Post, Anna Tampieri, Daniele Catalucci Inhalation of peptide-loaded nanoparticles improves heart failure published pages: eaan6205, ISSN: 1946-6234, DOI: 10.1126/scitranslmed.aan6205	Science Translational Medicine 10/424	2020-04-08
2017	Lorenzo Fassina, Giacomo Rozzi, Stefano Rossi, Simone Scacchi, Maricla Galetti, Francesco Paolo Lo Muzio, Fabrizio Del Bianco, Piero Colli Franzone, Giuseppe Petrilli, Giuseppe Faggian, Michele Miragoli Cardiac kinematic parameters computed from video of in situ beating heart published pages: 46143, ISSN: 2045-2322, DOI: 10.1038/srep46143	Scientific Reports 7	2020-04-08
2018	Vittoria Di Mauro, Maria Barandalla-Sobrados, Daniele Catalucci The noncoding-RNA landscape in cardiovascular health and disease published pages: , ISSN: 2468-0540, DOI: 10.1016/j.ncrna.2018.02.001	Non-coding RNA Research	2020-04-08

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CUPIDO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CUPIDO" are provided by the European Opendata Portal: CORDIS opendata.